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Objective: We performed a systematic review and meta-analysis to explore the association 
between CKD and mortality and procedural complications in TAVR. 
 
Background: The impact of varying stages of CKD or end-stage renal disease (ESRD) on 
patients receiving TAVR is not clearly identified. 
 
Methods: We searched the databases of MEDLINE and EMBASE from inception to May 
2018. Included studies were published TAVR studies that compared the risk of mortality and 
procedural complications in CKD patients compared to control patients. Data from each 
study were combined using the random-effects model.  
 
Results: Twelve studies (42,703 CKD patients and 51,347 controls) were included. 
Compared with controls, CKD patients had a significantly higher risk of 30-day overall 
mortality (risk ratio [RR]=1.56, 95% confidence interval [CI]: 1.34-1.80, I2=60.9), long-term 
cardiovascular mortality (RR=1.47, 95% CI: 1.20-1.81, I2=13.2%), and long-term overall 
mortality (RR=1.66, 95% CI: 1.45-1.91, I2=80.3), as well as procedural complications 
including pacemaker requirement (RR=1.20, 95% CI: 1.03-1.39, I2=56.1%) and bleeding 
(RR=1.60, 95% CI: 1.26-2.02, I2=86.0%). Risk of mortality and procedural complications 
increased with severity of CKD for stages 3, 4, and 5, respectively, in terms of long-term 
overall mortality (RR=1.28, 1.82, and 2.12), 30-day overall mortality (RR=1.26, 1.89, and 
1.93), long-term cardiovascular mortality (RR=1.18, 1.75, and 2.50), and bleeding (RR=1.19, 
1.63, and 1.83). 
 
Conclusions: Our meta-analysis demonstrates a significant increased risk of mortality and 
procedural complications in patients with CKD who underwent TAVR compared to controls. 










TAVR    transcatheter aortic valve replacement 
AS     aortic stenosis 
SAVR    surgical aortic valve replacement      
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Transcatheter aortic valve replacement (TAVR) is an increasingly common 
therapeutic procedure for symptomatic, moderate-severe aortic stenosis (AS). In these 
patients, this intervention is superior to medical therapy alone and has comparable results to 
the conventional surgical aortic valve replacement (SAVR) (1). TAVR is the treatment of 
choice for symptomatic AS in inoperable patients or patients with unacceptably high surgical 
risks (2).  
 Decreased renal function is associated with worse outcomes in many cardiovascular 
conditions, such as atherosclerosis, heart failure, pericardial and valvular disease and 
outcomes of cardiac interventions (3). More than 75% of patients with severe AS may have 
some degree of renal dysfunction(4, 5). Moreover, chronic kidney disease (CKD) is an 
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independent risk factor for mid-term mortality in patients with AS undergoing SAVR and 
TAVR (6). The impact of varying stages of CKD or end-stage renal disease (ESRD) on 
patients receiving TAVR is not clearly identified. 
  We sought to determine the effect of different stages of CKD on both short and long-
term overall and cardiovascular mortality in patients who underwent TAVR. Additional 
outcomes including pacemaker implantation, vascular complications, bleeding and 




 Two investigators (JK and PC) independently searched for published studies indexed 
in MEDLINE and EMBASE databases from inception to May 2018 using a search strategy, 
described in online supplementary document 1, that included the terms for “chronic kidney 
disease”, “aortic stenosis”, “transcatheter aortic valve replacement”, “complications”, 
“vascular complications”, “bleeding”, “pacemaker”, “cardiovascular mortality”, and 
“mortality”. Only English language publications were included. A manual search for 
additional pertinent studies and review articles using references from retrieved articles was 
also completed. 
Inclusion criteria 
The eligibility criteria included the following: 
(1)  Cohort study (prospective or retrospective) reporting incident mortality and 
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procedural complications, after the TAVR procedure. 
(2)  Reported relative risk, odds ratio, hazard ratio, incidence ratio, or standardized 
incidence ratio with 95% confidence intervals (CI), or sufficient raw data for their calculation  
(3) Participants without CKD as controls.  
Study eligibility was independently determined by two investigators (TR and CK) and 
differences were resolved by mutual consensus. Newcastle-Ottawa quality assessment scale 
was used to evaluate each study in three domains: recruitment and selection of the 
participants, similarity and comparability between the groups, and ascertainment of the 
outcome of interest among cohort studies (8).  
 
Data extraction 
 A standardized data collection form was used to obtain the following information 
from each study: title of study, name of first author, year of study, year of publication, 
country of origin, number of participants, demographic data of participants, method used to 
identify cases and controls, method used to diagnose outcomes of interest (mortality and 
procedural complications), average duration of follow-up, confounders that were adjusted, 
adjusted effect estimates with 95% CI, and covariates that were adjusted for the multivariable 
analysis. 
 To ensure accuracy, all investigators independently performed this data extraction 
process. Any data discrepancy was resolved by referring back to the original articles. 
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Definition of CKD 
 Chronic kidney disease was previously defined as the presence of kidney damage or 
decreased kidney function for three or more months, regardless of the cause, which was 
documented with International Classification of Diseases, Ninth Revision. The definition was 
introduced by the National Kidney Foundation, Kidney Disease Outcomes Quality Initiative, 
and modified by the international guideline group Kidney Disease Improving Global 
Outcomes (9, 10). Chronic kidney disease included in our study were CKD stages 3A to 
CKD stage 5 or glomerular filtration rate less than 60 ml/min/1.73 m2. Patients with 
glomerular filtration rate more than or equal to 60 ml/min/1.73 m2 were considered as part of 
the control group.  
 
Outcome definition 
Outcomes (overall mortality, cardiovascular mortality, pacemaker requirement, 
overall bleeding, major bleeding, cerebrovascular accident, major vascular complications, 
and overall vascular complications) were adjudicated according to Valvular Academic 
Research Consortium (VARC) criteria (11). Long-term overall mortality was defined as over-
all mortality at more than 30 days. 
 
Statistical analysis 
 We performed a meta-analysis of the included cohort studies using a random-effects 
model. Studies were excluded if they did not present an outcome in each intervention group 
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or did not have enough information required for continuous data comparison. We pooled the 
point estimates of risk ratio (RR) and rate ratio from each study using the generic inverse-
variance method of Der Simonian and Laird (12). The heterogeneity of effect size estimates 
across these studies was quantified using the I2 statistic. The I2 statistic ranges in value from 0 
to 100% (I2<25%, low heterogeneity; I2=25%–50%, moderate heterogeneity; and I2>50%, 
substantial heterogeneity) (13). A sensitivity analysis was performed to assess the influence 
of the individual studies on the overall results by omitting one study at a time. Publication 
bias was assessed using funnel plot and Egger’s regression test (14) (p<0.05 was considered 
significant). Potential sources of heterogeneity from clinical characteristics were analyzed 
with subgroup analysis and were compared with meta-regression. All data analyses were 
performed using Stata SE Statistical Software: Release 14.1, College Station, TX: StataCorp 
LP, StataCorp 2015.  
 
Sensitivity analysis 
We used a sequential exclusion strategy, as described by Patsopoulos and colleagues, 
to examine whether overall estimates were influenced by the substantial heterogeneity 
observed (15). In accordance with Cochrane, evidence of publication bias was examined 
through funnel plots if there were more than 10 available studies. Funnel plot asymmetry was 
further confirmed with Egger’s test. If asymmetry was present, we used the trim-and-fill 
method to adjust for publication bias. 
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Results 
Description of included studies 
  Our search strategy yielded 908 potentially relevant articles (568 articles from 
EMBASE and 340 articles from MEDLINE). After exclusion of 14 duplicate articles, 894 
articles underwent title and abstract review. Seven hundred forty-seven articles were 
excluded at this stage since they were not cohort studies, did not report the outcome of 
interest (mortality or compilations) or were not conducted in patients with CKD, leaving 147 
articles for full-length article review. One hundred and twenty four of the 147 studies were 
excluded, as they were descriptive studies without comparators. Two studies were excluded 
because the same group of authors used the same database. Nine more studies were excluded 
because of unclear outcome definition. Therefore, 8 retrospective and 4 prospective cohort 
studies with 42,703 CKD patients and 51,347 controls were included in this meta-analysis. 
Figure 1 outlines the search and literature review process. Summaries of the included studies 
and the clinical characteristics are shown in Table 1.  
Meta-analysis results 
Twelve studies (42,703 CKD patients and 51,347 controls) were included. Compared 
with controls, CKD patients had a significantly higher risk of 30-day overall mortality 
(RR=1.56, 95% CI: 1.34-1.80, I2=60.9) (Figure 2A) and 30-day cardiovascular mortality 
(RR=1.47, 95% CI: 1.20-1.81, I2=13.2%) (Figure 2B). CKD patients had a significantly 
higher risk of long-term cardiovascular mortality (RR=1.44, 95% CI: 1.22-1.70, I2=36.2%) 
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(Figure 3A) and long-term overall mortality (RR=1.66, 95% CI: 1.45-1.91, I2=80.3) (Figure 
3B).  
Interestingly, risk of long-term overall mortality increased with severity of CKD for 
stages 3, 4, and 5, respectively (RR=1.28, 1.82, and 2.12), 30-day overall mortality 
(RR=1.26, 1.89, and 1.93), and 30-day cardiovascular mortality (RR=1.18, 1.75, and 2.50). 
Regarding procedural complications, CKD significantly increased risk of 30-day 
pacemaker requirement (RR=1.20, 95% CI: 1.03-1.39, I2=56.1%) (Supplement Figure 1), 30-
day overall bleeding (RR=1.60, 95% CI: 1.26-2.02, I2=86.0%), and 30-day major bleeding 
(RR=1.40, 95% CI: 1.10-1.78, I2=88.2%)(Supplement Figure 2). CKD increased the risk of 
30-day major vascular complications (RR=1.19, 95% CI: 0.97-1.45, I2=0.0%) (Supplement 
Figure 3) as well as 30-day overall vascular complications (RR=1.06, 95% CI: 0.99-1.14, 
I2=0.0%)(Supplement Figure 4).  
Subgroup analysis of CKD stage 4 increased risk of cerebrovascular accident 
(RR=1.89, 95% CI: 1.22-2.94, I2=0.0%) but did not reach statistically significant in overall 
CKD when compare to control (RR=1.19, 95% CI: 0.95-1.50, I2=26.9%).  
Similar to risk of mortality, risk of 30-day overall bleeding increased with severity of 
CKD for stages 3, 4, and 5, respectively (RR=1.19, 1.63, and 2.12) (Figure 4A) as well as 30-
day major bleeding (RR=1.09, 1.12, and 1.86) (Figure 4B).  
Meta-regression was performed in 30-day overall mortality, long-term overall 
mortality, 30-day pacemaker implantation, and overall bleeding. Stages of CKD were 
significant sources of heterogeneity for 30-day overall mortality (p=0.024), long-term overall 
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mortality (p=0.001), and overall bleeding (p=0.021). As shown in subgroup analysis in 
Figure 2A, heterogeneity of 30-day overall mortality analysis decreased to 0%, 0%, and 
38.4% in CKD stage 3, 4, and 5 subgroups, respectively. Heterogeneity of long-term overall 
mortality also decreased to 55.8%, 50.2%, and 56.5% in CKD stage 3, 4, and 5 subgroup, 
respectively (Figure 3B). However, stages of CKD and high-risk preoperative evaluation 
were not significant sources of heterogeneity of 30-day pacemaker implantation (p=0.246 and 
p=0.355, respectively). According to sensitivity analysis, no study was found to be a source 
of heterogeneity in 30-day major bleeding, 30-day overall mortality, and long-term overall 
mortality.  
 
Quality assessment of included studies  
  Quality of each study was evaluated by two independent authors (PC, WV). The 
Newcastle-Ottawa scale (0 to 9) was used to evaluate included studies on 3 domains: 
selection, comparability, and outcomes. Higher scores represent higher study quality. The 
score of each study ranged from 7 to 9 which reflected high quality (Supplement Table 1). 
Intra-study risks of bias of included studies are also described in the supplement Table 2.  
Funnel plots of long-term overall mortality, long-term cardiovascular mortality, 30-
day overall mortality, and 30-day cardiovascular mortality are shown in Figure 5. Funnel 
plots were symmetric for long-term cardiovascular mortality and 30-day mortality. However, 
funnel plots were asymmetric for long-term overall mortality and 30-day cardiovascular 
mortality. By Egger’s test, there was significant publication bias regarding long-term overall 
This article is protected by copyright. All rights reserved.
mortality (p=0.019) and 30-day cardiovascular mortality (p=0.006). Funnel plots for 30-day 
cerebrovascular accident, 30-day pacemaker implantation, 30-day major bleeding, 30-day 
overall bleeding, and 30-day vascular complications were symmetric (not shown).  
 
Discussion 
To date, there is limited evidence regarding the association between varying CKD 
stages and outcomes in patients undergoing TAVR. Our study is the first meta-analysis to 
address the association between TAVR complications and CKD stages. 
Several comorbidities are known to be associated with poor outcomes in patients who 
receive TAVR. According to the Edwards SAPIEN Aortic Bioprosthesis European Outcome 
(SOURCE) Registry, which was conducted in 1,038 patients, CKD was among the strongest 
independent predictors of 30-day mortality in patients undergoing TAVR (17). A meta-
analysis published in 2018 (18) demonstrated an association between advanced CKD, 
including stages 4 and 5, and higher mortality in high-risk patients undergoing TAVR.  
However, this study did not demonstrate association between early and advanced stages of 
CKD and outcomes. Moreover, several studies that were included in that meta-analysis used 
CKD stage 4, instead of a normal kidney function control, as a control compared to CKD 
stage 5 (19, 20). Therefore, selection bias of cases and controls was, in our opinion, a major 
limitation in the previous meta-analysis..  
Previous work from Hansen et al. reported significantly increased mortality in stage 3 
CKD patients who underwent TAVR (21). However, most studies conducted prior to Hansen 
et al. (22-27) found this association insignificant. The association between stage 4 or 5 CKD 
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and increased mortality was reported as significant in later studies (16, 21, 22, 27, 28). Our 
meta-analysis demonstrated the association between CKD and 30-day overall mortality, 30-
day cardiovascular mortality, long-term cardiovascular mortality, and long-term overall 
mortality.   In meta-regression, stages of CKD also showed to be a significant source of 
heterogeneity thus confirming the significant correlation between the progression of stages of 
CKD and 30-day overall mortality, overall bleeding, and long-term overall mortality.  
CKD is an established risk factor for stroke (29, 30). Our study showed that CKD 
stage 4 was associated with increased 30-day cerebrovascular accidents. Nonetheless, the 
association was not significant in CKD stage 3 and stage 4. Since there were limited number 
of include studies that reported the incidence of stroke, this could be accountable from 
underpower of included studies.  
Several mechanisms lead to bleeding tendency in CKD patients. Platelet dysfunction 
progresses as chronic kidney disease advances. The mechanisms are attributed from 
multifactorial including uremic toxins, anemia, and increased nitric oxide (31). Our study 
revealed that CKD progression was associated with increased 30-day major bleeding. The 
association, however, was insignificant in CKD stage 3 and 4. This could be attributed from 
heterogeneity among studies and underpower.  
 
Limitations 
Our meta-analysis is not without limitations. First, included studies were prospective 
and retrospective cohorts that were observational in nature. Hence, they were subject to 
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confounders; however,  a randomized-controlled trial would be impractical. Second, certain 
outcomes reported in the studies varied slightly in their definitions and durations. Random-
effect modeling was, therefore, used for the the meta-analysis. Third, the included studies 
were conducted mostly in Caucasian populations.   
 
Conclusion 
 Stage of CKD prior to procedure positively correlated with overall bleeding 
complication, 30-day mortality, and long-term overall mortality in patients undergoing 
TAVR. The presence of CKD, from early to advanced stages, provides prognostic 





Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram of search strategy and included studies.  
Figure 2: Forest plot of 30-day overall mortality (2A) and 30-day cardiovascular mortality 
(2B) according to stage of CKD. 
Figure 3: Forest plot of long-term overall mortality (3) increased and long-term 
cardiovascular mortality (3) according to stage of CKD. 
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Figure 4: Forest plot of 30-day overall bleeding increased with severity of CKD (Figure 4A) 
as well as 30-day major bleeding (Figure 4B). 
Figure 5: Funnel plots of long-term overall mortality (A), long-term cardiovascular mortality 
(B), 30-day mortality (C), and 30-day cardiovascular mortality (D) 
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Table 1: Summaries of the included studies and the clinical characteristics 
Supplement Table 1: Newcastle-Ottawa quality assessment scale of included studies in 
meta-analysis 
Supplement Table 2: Intra-study risk of bias of included studies in meta-analysis 
Supplement document 1: Search keywords 
Supplement Figure 1: Forest plot of 30-day 30-day pacemaker requirement with severity of CKD 
Supplement Figure 2: Forest plot of 30-day major bleeding with severity of CKD 
Supplement Figure 3: Forest plot of 30-day major vascular complications with severity of CKD 
Supplement Figure 4: Forest plot of 30-day overall vascular complications with severity of CKD 
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Outcome Definition Conclusion by Authors 













CKD stage 1-2 (eGFR≥60 
mL/min/1.73 m2), stage3 
(30-59 mL/min/1.73 m2), 
stage4 (15-29 mL/min/1.73 
m2) and stage 5 (<15 
mL/min/1.73 m2) 








Advanced CKD was 
associated with a higher 
rate of early and late 
mortality and bleeding 
events following TAVR 





patients of the 
institutions 




or in dialysis 
eGFR ≥60 mL/min/1.73 
m2, between 30 and 59 
mL/min/1.73 m2, and 
between 15 and 29 
mL/min/1.73 m2 
364 42.3 100 82.4 Overall mortality, 





Patients with severe 
chronic renal disease 
presented higher risk of 
adverse events.  
















eGFR: >60 mL/min/1.73 
m2 (group I), 31 to 60 
mL/min/1.73 m2 (group II), 
≤30 mL/min/1.73 m2 
(group III), and dialysis 
(group IV). 
1,204 44.7 100 81.5 Major bleeding, 
major vascular 
complications, 







Advanced CKD and 
dialysis are associated with 
increased rates of all-cause 
and CVS mortality, major 
and life-threatening 
bleeding, and vascular 
complications.  






admitted with a 
diagnosis of 
severe AS who 














CKD stages 3b to 5 1,057 63.2 0 79.9 All-cause mortality 




CKD stages 3b to 5 
increases the risk of 
mortality after TAVR and 
SAVR. The risk of AKI 
was higher after SAVR.  
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procedures 












Normal eGFR (≥90 
mL/min), mild (60-89 
mL/min), moderate (30-59 
mL/min), and severe (<30 
mL/min) CKD and those 
on chronic hemodialysis 
(HD). 
942 53.8 71.6 81.0 1-year survival, 30-
day all-cause and 
CVS mortality, MI, 
stroke vascular and 
bleeding 
complications, AKI, 
device success, and 
30-day combined 
safety end point 
Patients with CKD 
undergoing TAVR have a 
higher-risk profile and 
worse 30-day and 1-year 
outcomes. Chronic HD and 
severe preprocedural CKD 
are independently 
associated with an 
increased risk of 1-year 
mortality after TAVR. 












eGFR ≥60 mL/min/1.73 
m2; 45-59 mL/min/1.73 m2 
(CKD stage 3a); 30-44 
mL/min/1.73 m2 (CKD 
stage 3b); 15-29 
mL/min/1.73 m2 (CKD 
stage 4); and <15 
mL/min/1.73 m2 (CKD 
stage 5) 
6,464 53.4 75.0 82.9 The incidence of 
dialysis requirement 
after TAVR 
The patients established on 
dialysis before TAVR had a 


















CKD stage 3 and worse, 
AKI (elevation of 
creatinine of 0.3 mg/dL or 
greater, decrease of GFR 
of greater than 25%, or the 
need of RRT) 




AKI, RRT, new 
pacemaker, 
reoperation 
Preoperative CKD does not 
increase the risk of 
mortality and AKI after 
TAVR.  




All patients age 





Patients with CKD were 
identified using ICD-9-CM 
codes 35.05 and 35.06 
41,025 52.3 NA 81.1 All-cause in-hospital 
mortality, CVS 








Patients with CKD or 
ESRD have worse in-
hospital outcomes after 
TAVR. AKI is associated 
with higher in-hospital 
mortality in patients 
undergoing TAVR. 








CKD has 5 stages, 
organized by eGFR (CKD 
44,778 51.3
3 
NA 81.96 Death from any 
cause, new 
Increasing CKD stage 
leads to an increased risk 
















valve repair or 
mitral leaflet 
clip 
stage 1 = eGFR >90 
ml/min/m2, stage 2 = GFR 
60 to 89 ml/min/m2, stage 
3 = eGFR of 30 to 59 
ml/min/m2, stage 4 = GFR 
of 15 to 29 ml/min/m2, 
stage 5 = eGFR <15 
ml/min/m2). Combined 
stages 1 and 2 serving as a 
control group. 
 
requirement of RRT, 
or a composite of 
both. 
of death and/or RRT. 
Continuous analysis 
showed significant 
differences in outcomes in 
all levels of CKD when 
eGFR <60 ml/min/m2. 















eGFR > 60 mL/min, eGFR 
31 to 60 mL/min, and 
eGFR ≤ 30 mL/min 







length of stay, 
contrast load 
Worsening renal function 
was associated with 
increased in-hospital 
mortality, hospital length 
of stay, and ICU length of 
stay in SAVR patients, but 
not in TAVR patients 











CKD group (eGFR < 60 
mL/min/1.73 m2) and No-
CKD group (eGFR > 60 
mL/min/1.73 m2) 
118 57 61 81.3 Mortality, MI, 
vascular 
complications, 
overall length of 
stay 
TAVR is safe for patients 
with CKD. The presence of 
pre-existing DM and 
elevated pre-operative 
serum creatinine appear to 
confer a greater risk of 
developing AKI. 


















eGFR > 60 mL/min, GFR 
31 to 60 mL/min, and GFR 
≤ 30 mL/min 






dialysis, MI, major 
vascular 
complications 
Preoperative severe renal 
disease is a significant 
predictor for all-cause 1-












died within 24 h 
after TAVR or 
Pre-procedural eGFR ≤60 
mL/min, equivalent to 
CKD stage ≥3 
199 81.1 100 44.8 Renal function, 
renal replacement 
therapy, 30-day 
TAVR with the CoreValve 
prosthesis does not seem to 
bear an increased risk for 
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undergoing 




chronic HD or 
in need for pre-
interventional 
RRT 
mortality patients with CKD. For 
surgical high-risk patients 
with severe AS, a more 
consideration for TAVR 











CKD stage 1+2, CKD 
stage 3a, CKD stage 3b, 
and CKD stage 4 on the 
basis of eGFR ≥60, 45-59, 
30-44, and 15-29 
mL/min/1.73 m2, 
respectively. 
642 48.1 100 83.5 Length of hospital 
stay, mortality, MI, 
stroke, AKI, need 






Classification of CKD 
stages before TAVR 
allows risk stratification 
for early and midterm 
clinical outcomes. TAVR 
for patients with CKD 
stage 4 is still considered 
challenging because of 




Table 1: Summaries of the included studies and the clinical characteristics 
ACC: American College of Cardiology, AF: atrial fibrillation, AKI: acute kidney injury, AS: aortic stenosis, CKD: chronic kidney disease, CVS: cardiovascular, eGFR: 
estimated glomerular filtration rate, ESRD: end stage renal disease, HD: hemodialysis, ICD: international classification of disease, ICU: intensive care unit, MI: myocardial 
infarction, RRT: renal replacement therapy, SAVR: surgical aortic valve replacement, STS:  Society for Thoracic Surgeon, TAVR: transcatheter aortic valve replacement, 
TVT: transcatheter valve therapy, UK: United Kingdom, USA: United States.  
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Outcome Definition Conclusion by Authors 













CKD stage 1-2 (eGFR≥60 
mL/min/1.73 m2), stage3 
(30-59 mL/min/1.73 m2), 
stage4 (15-29 mL/min/1.73 
m2) and stage 5 (<15 
mL/min/1.73 m2) 








Advanced CKD was 
associated with a higher 
rate of early and late 
mortality and bleeding 
events following TAVR 





patients of the 
institutions 




or in dialysis 
eGFR ≥60 mL/min/1.73 
m2, between 30 and 59 
mL/min/1.73 m2, and 
between 15 and 29 
mL/min/1.73 m2 
364 42.3 100 82.4 Overall mortality, 





Patients with severe 
chronic renal disease 
presented higher risk of 
adverse events.  
















eGFR: >60 mL/min/1.73 
m2 (group I), 31 to 60 
mL/min/1.73 m2 (group II), 
≤30 mL/min/1.73 m2 
(group III), and dialysis 
(group IV). 
1,204 44.7 100 81.5 Major bleeding, 
major vascular 
complications, 







Advanced CKD and 
dialysis are associated with 
increased rates of all-cause 
and CVS mortality, major 
and life-threatening 
bleeding, and vascular 
complications.  






admitted with a 
diagnosis of 
severe AS who 















CKD stages 3b to 5 1,057 63.2 0 79.9 All-cause mortality 




CKD stages 3b to 5 
increases the risk of 
mortality after TAVR and 
SAVR. The risk of AKI 
was higher after SAVR.  












Normal eGFR (≥90 
mL/min), mild (60-89 
mL/min), moderate (30-59 
mL/min), and severe (<30 
mL/min) CKD and those 
on chronic hemodialysis 
(HD). 
942 53.8 71.6 81.0 1-year survival, 30-
day all-cause and 
CVS mortality, MI, 
stroke vascular and 
bleeding 
complications, AKI, 
device success, and 
30-day combined 
Patients with CKD 
undergoing TAVR have a 
higher-risk profile and 
worse 30-day and 1-year 
outcomes. Chronic HD and 
severe preprocedural CKD 
are independently 
associated with an 
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safety end point increased risk of 1-year 
mortality after TAVR. 












eGFR ≥60 mL/min/1.73 
m2; 45-59 mL/min/1.73 m2 
(CKD stage 3a); 30-44 
mL/min/1.73 m2 (CKD 
stage 3b); 15-29 
mL/min/1.73 m2 (CKD 
stage 4); and <15 
mL/min/1.73 m2 (CKD 
stage 5) 
6,464 53.4 75.0 82.9 The incidence of 
dialysis requirement 
after TAVR 
The patients established on 
dialysis before TAVR had a 


















CKD stage 3 and worse, 
AKI (elevation of 
creatinine of 0.3 mg/dL or 
greater, decrease of GFR 
of greater than 25%, or the 
need of RRT) 




AKI, RRT, new 
pacemaker, 
reoperation 
Preoperative CKD does not 
increase the risk of 
mortality and AKI after 
TAVR.  




All patients age 





Patients with CKD were 
identified using ICD-9-CM 
codes 35.05 and 35.06 
41,025 52.3 NA 81.1 All-cause in-hospital 
mortality, CVS 








Patients with CKD or 
ESRD have worse in-
hospital outcomes after 
TAVR. AKI is associated 
with higher in-hospital 
mortality in patients 
undergoing TAVR. 























valve repair or 
mitral leaflet 
clip 
CKD has 5 stages, 
organized by eGFR (CKD 
stage 1 = eGFR >90 
ml/min/m2, stage 2 = GFR 
60 to 89 ml/min/m2, stage 
3 = eGFR of 30 to 59 
ml/min/m2, stage 4 = GFR 
of 15 to 29 ml/min/m2, 
stage 5 = eGFR <15 
ml/min/m2). Combined 





NA 81.96 Death from any 
cause, new 
requirement of RRT, 
or a composite of 
both. 
Increasing CKD stage 
leads to an increased risk 
of death and/or RRT. 
Continuous analysis 
showed significant 
differences in outcomes in 
all levels of CKD when 
eGFR <60 ml/min/m2. 













eGFR > 60 mL/min, eGFR 
31 to 60 mL/min, and 
eGFR ≤ 30 mL/min 







Worsening renal function 
was associated with 
increased in-hospital 
mortality, hospital length 
of stay, and ICU length of 
stay in SAVR patients, but 
not in TAVR patients 
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Healthcare 
Hospitals 
length of stay, 
contrast load 











CKD group (eGFR < 60 
mL/min/1.73 m2) and No-
CKD group (eGFR > 60 
mL/min/1.73 m2) 
118 57 61 81.3 Mortality, MI, 
vascular 
complications, 
overall length of 
stay 
TAVR is safe for patients 
with CKD. The presence of 
pre-existing DM and 
elevated pre-operative 
serum creatinine appear to 
confer a greater risk of 
developing AKI. 


















eGFR > 60 mL/min, GFR 
31 to 60 mL/min, and GFR 
≤ 30 mL/min 






dialysis, MI, major 
vascular 
complications 
Preoperative severe renal 
disease is a significant 
predictor for all-cause 1-
















died within 24 h 
after TAVR or 
patients on 
chronic HD or 
in need for pre-
interventional 
RRT 
Pre-procedural eGFR ≤60 
mL/min, equivalent to 
CKD stage ≥3 




TAVR with the CoreValve 
prosthesis does not seem to 
bear an increased risk for 
patients with CKD. For 
surgical high-risk patients 
with severe AS, a more 
consideration for TAVR 











CKD stage 1+2, CKD 
stage 3a, CKD stage 3b, 
and CKD stage 4 on the 
basis of eGFR ≥60, 45-59, 
30-44, and 15-29 
mL/min/1.73 m2, 
respectively. 
642 48.1 100 83.5 Length of hospital 
stay, mortality, MI, 
stroke, AKI, need 






Classification of CKD 
stages before TAVR 
allows risk stratification 
for early and midterm 
clinical outcomes. TAVR 
for patients with CKD 
stage 4 is still considered 
challenging because of 




Table 1: Summaries of the included studies and the clinical characteristics 
ACC: American College of Cardiology, AF: atrial fibrillation, AKI: acute kidney injury, AS: aortic stenosis, CKD: chronic kidney disease, CVS: cardiovascular, eGFR: 
estimated glomerular filtration rate, ESRD: end stage renal disease, HD: hemodialysis, ICD: international classification of disease, ICU: intensive care unit, MI: myocardial 
infarction, RRT: renal replacement therapy, SAVR: surgical aortic valve replacement, STS:  Society for Thoracic Surgeon, TAVR: transcatheter aortic valve replacement, 
TVT: transcatheter valve therapy, UK: United Kingdom, USA: United States.  
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